GAO’s reports and testimonies give Congress, federal agencies, and the public timely, fact-based, non-partisan information that can improve government operations and save taxpayers billions of dollars.
Since May 2020, federal efforts to speed the development, manufacturing, and distribution of COVID-19 vaccines—previously known as Operation Warp Speed—have been led by the Departments of Health and Human Services and Defense.
In 2020, the federal government and the state of South Dakota sponsored Fourth of July celebrations and related events in Washington, D.C., and at the Mount Rushmore National Memorial in South Dakota—all during the COVID-19 pandemic.
DOD's more than 73,000 enlisted medical personnel serve in roles ranging from paramedics to imaging technicians, and must be ready to use their wartime medical skills to care for injured and ill servicemembers.
However, DOD could do more to define, track, and assess wartime medical skills.
The Department of Defense received about $10.5 billion to help it respond to COVID-19. We examined DOD's strategy for protecting servicemembers as well as its research and development work on vaccines, testing, and more.
To help address the growing rate of military suicides, DOD provides clinical treatment such as medication to servicemembers. DOD has also implemented various non-clinical suicide prevention efforts, such as distributing gun locks and providing suicide awareness training.
Remdesivir was the first drug approved by the Food and Drug Administration to treat COVID-19. Gilead Sciences, Inc., originally developed it to treat other viral diseases.
We reviewed federal contributions to development of remdesivir and related agency patent rights.
As of Dec.